Jolanta B. Zawilska
Monika Kacela
Piotr Adamowicz- 1Department of Pharmacodynamics, Medical University of Łódź, Łódź, Poland
- 2Department of Forensic Toxicology, Institute of Forensic Research, Kraków, Poland
Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and highly efficacious agonists of serotonin 5-HT2A and 5-HT2C receptors (Ki values in low nanomolar range) with more than 1000-fold selectivity for 5-HT2A compared with 5-HT1A. They display higher affinity for 5-HT2A receptors than their 2C counterparts and have markedly lower affinity, potency, and efficacy at the 5-HT2B receptor compared to 5-HT2A or 5-HT2C. The drugs are sold as blotter papers, or in powder, liquid, or tablet form, and they are administered sublingually/buccally, intravenously, via nasal insufflations, or by smoking. Since their introduction in the early 2010s, numerous reports have been published on clinical intoxications and fatalities resulting from the consumption of NBOMe compounds. Commonly observed adverse effects include visual and auditory hallucinations, confusion, anxiety, panic and fear, agitation, uncontrollable violent behavior, seizures, excited delirium, and sympathomimetic signs such mydriasis, tachycardia, hypertension, hyperthermia, and diaphoresis. Rhabdomyolysis, disseminated intravascular coagulation, hypoglycemia, metabolic acidosis, and multiorgan failure were also reported. This survey provides an updated overview of the pharmacological properties, pattern of use, metabolism, and desired effects associated with NBOMe use. Special emphasis is given to cases of non-fatal and lethal intoxication involving these compounds. As the analysis of NBOMes in biological materials can be challenging even for laboratories applying modern sensitive techniques, this paper also presents the analytical methods most commonly used for detection and identification of NBOMes and their metabolites.
Introducttion
The last decade witnessed the emergence of new psychoactive substances (NPSs), followed by a rapid increase in their prevalence and the constant introduction of new compounds into the clandestine market in order to circumvent the existing laws. From 2009 to 2018, 899 different NPSs were reported worldwide (United Nations Office on Drugs and Crime [UNODC], 2019). Over the course of 2018, a total of 687 NPSs were notified to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). In 2018, one new NPS was reported to EMCDDA every week (EMCDDA, 2019). The five main classes of NPSs are synthetic cannabinomimetics, stimulants (dominated by derivatives of cathinone), opioids, psychedelics, and non-pharmaceutical benzodiazepines. By analogy to other NPSs, psychedelic compounds, which produce marked alterations of perception, mood, and cognition, are widely used for recreational purposes. Psychedelics (also called classical or serotoninergic hallucinogens) are divided into two main groups based on their chemical structure: indoleamines (termed also indolealkylamines; e.g., ergolines, including LSD and its analogs, and simple tryptamines, such as N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine) and phenylalkylamines. Phenylalkylamines are highly selective for serotonin 5-HT2 receptors, while indoleamines are relatively non-selective for 5-HT receptors, displaying moderate to high affinity for 5-HT1 and 5-HT2 receptor subtypes. The phenylalkylamines can be further divided into two subgroups, one group being the phenylisopropylamines (analogs of amphetamine), e.g., 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-methylamphetamine (DOM), and the other being the phenethylamines, including mescaline, 2C-X compounds and their derivatives (Figure 1) (reviewed by Halberstadt, 2017). The name “2C” refers to an acronym created by the ‘godfather’ of psychedelic drugs Alexander Shulgin to describe their chemical structure, where two carbon atoms separate the amine group from the phenyl ring (Shulgin and Shulgin, 1991). The prototype of the 2C series, 2C-B, was synthesized by Shulgin in 1974. Since 2010, a new group of 2C compounds containing an N-(2-methoxy)benzyl (N-benzoylmethoxy) substituent, known as N-(2-methoxybenzyl)phenethylamines (aka 25X-NBOMes or simply NBOMes), has emerged in the illicit drug market. Structure-activity studies indicate that this substituent significantly increases the affinity of the drug toward the 5-HT2A receptor and its pharmacological activity (Hansen et al., 2014). It is important to note that stimulation of the 5-HT2A receptors is required for the psychedelic effects of compounds such as LSD, mescaline, and psilocybin (Glennon et al., 1984; Titeler et al., 1988; Sadzot et al., 1989; Vollenweider et al., 1998; Rickli et al., 2016). The first NBOMes were originally synthesized by Ralf Heim at the Free University of Berlin in a search for pharmacological tools to study the 5-HT2A receptor (Heim, 2003). Since then, [11C]25I-NBOMe and [11C]25C-NBOMe have been used to map the distribution of 5-HT2A receptors in the brain by positron emission tomography (PET) imaging (Ettrup et al., 2010, 2014; for an excellent review see Poulie et al., 2019).
Figure 1. Chemical structures of main classes of psychedelics.
The first recreationally used drug from this group was 25I-NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine), identified in seven green blotters seized by the Swedish police in May 2012 (EMCDDA, 2014). It is likely that 25I-NBOMe was the first NBOMe to be used recreationally in the United States (Palamar and Le, 2019). Following this, several potent NBOMes were synthesized and introduced into the drug market. In these, the iodine atom was exchanged for other halogens: e.g., bromine (25B-NBOMe) or chlorine (25C-NBOMe), a hydrogen atom (25H-NBOMe), a nitro group (25N-NBOMe) or an organic functional group, - methyl (25D-NBOMe), -ethyl (25E-NBOMe), or –isopropyl (25iP-NBOMe) (Wood et al., 2015; Poulie et al., 2019). Three compounds from this group, namely 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe, accounted for 0.03% of the total quantity of hallucinogens (other than ketamine) seized globally between 2011 and 2017 (United Nations, 2019). In the United States, 2,129 reports for 25I-NBOMe, 1,273 reports for 25C-NBOMe, and 924 reports for 25B-NBOMe were collected by the System to Retrieve Information from Drug Evidence and the National Forensic Laboratory Information System between January 2014 and April 2018 (Drug Enforcement Administration, 2018).
Methods
This literature review was based on an exhaustive search of PubMed (U.S. National Library of Medicine) that used “NBOMe” and each of the compound names listed in Table 1 as keywords. Only papers written in English and with full texts available by November 2019 were included. Additionally, official reports published by the United Nations Office on Drugs and Crime (UNODOC), EMCDDA, and the World Health Organization (WHO) were studied. Furthermore, in each article and report obtained, references were checked carefully in order to identify possible additional publications missed during the initial search.
Pharmacology of NBOMes
In vitro studies indicated that NBOMe compounds are ultrapotent and highly efficacious agonists of 5-HT2A and 5-HT2C receptors (Ki values in low nanomolar range), with more than 1000-fold selectivity for 5-HT2A compared with 5-HT1A. The compounds display higher affinity for 5-HT2A receptors than their 2C counterparts and have markedly lower affinity, potency, and efficacy at the 5-HT2B receptor than at 5-HT2A or 5-HT2C (Juncosa et al., 2013; Nichols et al., 2015; Rickli et al., 2015; Elmore et al., 2018; Eshleman et al, 2018). In addition, NBOMes have a significant affinity (Ki < 300 nM) for adrenergic α1 receptors but not so H1-histamine, dopamine D1, D2, and D3 receptors or the monoamine transporters DAT, NET, or SERT (Nichols et al., 2015; Elmore et al., 2018; Eshleman et al, 2018). Molecular modeling and molecular dynamics simulation studies performed on a human 5-HT2A receptor model identified several amino acid residues as putative binding sites of NBOMes. It is suggested that the binding pocket, localized among transmembranes (TM) III, V, VI, and VII, includes Trp-151(TMIII), Ile-152(TMIII), Asp-155(TMIII), Ser-159(TMIII), Ser-239(TMV), Phe-339 (TMVI), Phe-340(TMVI), Val-336(TMVII), and Tyr-370(TMVII) (Braden et al., 2006; Silva et al., 2011; Ísberg et al., 2011). Among them, a highly conserved Asp-155 forms a salt bridge with the amine nitrogen, Ser-159 and Ser-239 form H-bonds with the 2-methoxy and 5-methoxy group, respectively, and Phe-340 forms a van der Waals interaction with the benzene ring. It should be emphasized that Asp-155, Ser-159, Ser-239, Phe-340 are also important for binding and efficacy of different agonists and partial agonists at 5-HT2A receptor (Silva et al., 2011). On the other hand, the van der Waals interaction between Phe-339 and N-benzyl ring of NBOMes and the hydrogen bond formed by Tyr-370 with the 2-position oxygen on this ring are considered to play a key role in the high potency and affinity of these compounds binding to 5-HT2A receptor (Silva et al., 2011; Ísberg et al., 2011).
The activation of cortical 5-HT2A receptors induces the head twitch response (HTR) in mice and rats, also referred to as wet dog shakes (Willins and Meltzer, 1997; Abiero et al., 2019). The HTR is widely used as a behavioral marker for hallucinogen effects in humans (Halberstadt and Geyer, 2018). 25C-NBOMe, 25I-NBOMe, and 25B-NBOMe induced an HTR response in rodents with a potency several-fold higher than their 2C counterparts, 2C-C and 2C-I (Halberstadt and Geyer, 2014; Elmore et al., 2018; Custodio et al., 2019; Herian et al., 2019). Two lines of evidence support a notion that this behavioral effect is mediated by cortical 5-HT2A receptors. Thus, ketanserin, a 5-HT2A antagonist, blocked the 25B-NBOMe-evoked HTR and normalized 5-HT2A mRNA levels in the mouse prefrontal cortex upregulated by a prolonged administration of the drug (Custodio et al., 2019).
Gatch et al. (2017) tested 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe for discriminative stimulus effects similar to a prototypical psychedelic/hallucinogen DOM and to an empathogen, 3,4-methylenedioxymethamphetamine (MDMA). In DOM-trained rats 25B-NBOMe and 25C-NBOMe, but not 25I-NBOMe, fully substituted for this drug. 25B-NBOMe also fully substituted for MDMA. In both tests, the dose-effect curves for 25B-NBOMe had an inverted U-shape. It is suggested that 25B-NBOMe and 25C-NBOMe are most likely used as recreational psychedelics, although 25B-NBOMe may also be used as an empathogenic compound (Gatch et al., 2017). However, the latter assumption should be taken with caution, as some compounds (e.g., fenfluramine) that substitute for MDMA in rats do not produce MDMA-like empathogenic effects in humans (Schechter, 1988).
Using a battery of tests, behavioral effects of 25I-NBOMe (0.5 and 1 mg/kg) were examined in male and female Sprague-Dawley rats (Miliano et al., 2019). In both sexes, the systemic administration of the drug reduced visual object and placing responses–an effect likely related to its pro-hallucinogenic action–and decreased acoustic and tactile responses. Furthermore, by analogy to LSD and MDMA (Halberstadt and Geyer, 2010; Marti et al., 2019), 25I-NBOMe impaired the acoustic startle response [prepulse inhibition, a preclinical behavioral marker of vulnerability to develop a neuropsychiatric disorder (Marti et al., 2019)]. The drug increased body temperature only in females. On the other hand, it exerted an analgesic affect in males. It is suggested that the observed differences could be related to a sex-dependent pharmacodynamic profile of 25I-NBOMe (Miliano et al., 2019).
Psychedelic drugs interact with various neurotransmitter systems, namely serotonergic, glutamatergic, dopaminergic, cholinergic, and GABA-ergic. Among them, the glutamatergic system appears to play a prominent role in the action of these drugs (Aghajanian and Marek, 1999). In vivo microdialysis after systemic administration to rats of DOI, 5-methoxy-N,N-diisopropyltryptamine (MeO-DIPT) or LSD revealed markedly elevated extracellular levels of glutamate in the cortex (Scruggs et al., 2003; Muschamp et al., 2004; Noworyta-Sokołowska et al., 2016, 2019). DOI also increased the dopamine level in the cortex and ventral tegmental area (VTA) (Bortolozzi et al., 2005; Pehek et al., 2006). Recently, Herian et al. (2019), using microdialysis in freely moving male Wistar-Han rats, demonstrated increased extracellular levels of glutamate, dopamine, and 5-HT in the frontal cortex after administration of 25I-NBOMe. The drug also increased the tissue content of 5-HT and its metabolite hydroxyindoleacetic acid (5-HIAA) but did not affect the tissue content of dopamine and its metabolites: 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA). Subsequent studies performed by Miliano et al. (2019) on Spague-Dawley rats, both males and females, showed that 25I-NBOMe increased extracellular dopamine levels in the nucleus accumbens (NAc) shell (but not core) in a sex-independent way. The drug markedly elevated dopamine levels in the medial prefrontal cortex (mPFC) of females but not males. No statistically significant changes in extracellular levels of 5-HT in the three analyzed brain structures were found in both sexes (Miliano et al., 2019). These results suggest that in rats effects of 25I-NBOMe on dopaminergic and serotoninergic transmission depend not only on the brain structure but also strain and sex.
An important question that remains to be fully resolved is whether NBOMe compounds are endowed with an abuse potential. Two behavioral tests, conditioned place preference (CPP) and self-administration (SA), are widely used in studies examining the abuse potential of drugs by analyzing their rewarding and reinforcing effects. 25I-NBOMe (0.3 mg/kg), 25B-NBOMe (1 mg/kg), and 25N-NBOMe (3 mg/kg) produced CPP in mice with a magnitude comparable to 1 mg/kg of methamphetamine (Custodio et al., 2019; Jeon et al., 2019; Seo J.Y. et al., 2019). The 25B-NBOME-elicited CPP was blocked by antagonists of D1- and D2-dopamine receptors, SCH 23390 and haloperidol, respectively, but was not affected by ketanserin, an observation indicating an important role of dopaminergic transmission in this phenomenon (Custodio et al., 2019). In the SA test performed on mice, 25B-NBOMe used at doses of 0.03, 0.1 and 0.3 mg/kg/infusion significantly increased both a number of infusions/session and an active lever pressing/session, albeit with a weaker potency than methamphetamine (Custodio et al., 2019). On the contrary, 25N-NBOMe (0.01 mg/kg/infusion) weakly increased the number of infusions/session, but not the active lever pressing/session in mice (Seo J.Y. et al., 2019), whereas 25I-NBOMe (0.03 mg/kg/infusion) did not significantly affect these two SA parameters in rats (Jeon et al., 2019). These findings suggest that 25I-NBOMe, 25B-NBOMe, and 25N-NBOMe might have some dependence liability.
As activation of the mesolimbic dopaminergic pathway plays a critical role in drug abuse and addiction, effects of 25N-NBOMe and 25B-NBOMe on the expression of D1- and D2-dopamine receptors, dopamine transporter (DAT), and tyrosine hydroxylase (TH) at the protein level were examined in two studies. One was performed on mice that, in the course of the CPP test, received in total four injections of 25N-NBOMe (3 mg/kg/injection) and were sacrificed two days after the last injection (Seo J.Y. et al., 2019). In the second study, mice were repeatedly treated with 25B-NBOMe (1 mg/kg) for 7 days; they were sacrificed 30 min after the last injection (Custodio et al., 2019). Results of these studies are, however, not uniform. The level of D1 receptor protein was increased in the NAc of mice pretreated with 25B-NBOMe but was not affected in NAc and dorsal striatum (DSt) of 25N-NBOMe mice. Markedly lower levels of D2 receptors were found in the ventral tegmental area (VTA) after administration of 25B-NBOMe, in NAc and DSt (25N-NBOMe and 25B-NBOMe). 25N-NBOME decreased expression of DAT and TH in the NAc but not in DSt. 25B-NBOMe-induced a decrease of DAT and did not change TH protein levels in the VTA. Among several factors that might contribute to the above discrepancies, different dosing protocols appears to play an important role.
Toxicity In Vitro
Recent studies demonstrated that NBOMes exhibit neurotoxic and cardiotoxic activity. 25C-NBOMe was cytotoxic against neuronal cell lines SH-SY5Y, PC12, and SN4741 with respective calculated IC50 values of 89, 78, and 62 μM. The compound was 56, 25, and 64 times more potent than methamphetamine at reducing the viability of SH-SY5Y, PC12, and SN4741 cells, respectively. The neurotoxic action of 25C-NBOMe involves activation of the MAP/ERK cascade and inhibition of the Akt pathway (Xu et al., 2019). Acute (30 min) and prolonged (5 h) exposure of primary rat cortical cultures to 25B-NBOMe decreased spontaneous neuronal activity, measured as firing rate and burst rate (Zwartsen et al., 2018, 2019). The compound was 10-fold more potent than its precursor, 2C-B. Importantly, neuronal activity did not recover after 19 h of washout following prolonged exposure to 10 and 30 μM of 25B-NBOMe (Zwartsen et al., 2019).
25D-NBOMe and 25C-NBOMe reduced viability of H9c2 cells (cardiomyocytes). Both compounds used at doses of 0.75 and 2 mg/kg downregulated expression levels of p21 (CDC42/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects, and prolonged QT intervals in rat ECG. 25D-NBOMe inhibited the hERG potassium channel, a phenomenon that might play a role in QT interval prolongation (Yoon et al., 2019).
Available Forms of Products and Pattern of Use
The three most popular compounds from the 25X-NBOMe series are 25I-NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine), 25B-NBOMe (2-(4- bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine), and 25C-NBOMe (2-(4-chloro-2,5-dimethoxy phenyl)-N-[(2-methoxyphenyl)methyl]ethanamine) (Figure 1; Al-Iman and AbdulMajeed, 2017; Halberstadt, 2017; Palamar and Le, 2019). 25I-NBOM is known under street names “Solaris”, “25I”, “Dots”, “legal acid”, “N-Bomb”, “NE-BOME”, “Smiles”, “INBMeO”, “BOM-Cl”, “Hoffman”, “N-boom”, and “Holand Film”; 25C-NBOMe as “C-Boom”, “Cimbi-82”, “Pandora”, and “Dime”; and 25B-NBOMe as “Nova”, “legal acid”, “NBomb”, “NE-BOME”, “New Nexus”, “NBOMe-2-B”, and “BOM 2-CB” (Zuba et al., 2013; EMCDDA, 2014; World Health Organization, 2014a, b; Al-Iman and AbdulMajeed, 2017).
NBOMes are typically available in the form of preloaded paper doses (blotters) with images and logos from popular cartoons and music/movie posters and, less frequently, in powder or liquid form (Zuba et al., 2013; EMCDDA, 2014; World Health Organization, 2014a, b; Andrabi et al., 2015; Halberstadt, 2017). As NBOMes undergo extensive first-pass metabolism (see section BIOTRANSFORMATION), preferred and common patterns of their use include sublingual, buccal, and nasal. Thus, 25C-NBOMe and 25I-NBOMe are usually taken by holding the blotter in the mouth (sublingually or buccally), insufflated as powder, or in solution as a nose spray (Zuba et al., 2013; EMCDDA, 2014; Lawn et al., 2014; World Health Organization, 2014a, b; Nikolaou et al., 2015; Suzuki et al., 2015; Halberstadt, 2017; Marchi et al., 2019). In order to improve buccal absorption, 25I-NBOMe may be complexed with cyclodextrin. Other less common routes of administration include oral, rectal, vaginal, intravenous or intramuscular injection, and smoking (EMCDDA, 2014; World Health Organization, 2014a, b). Doses and duration of action depend on the route of administration (see Table 1).
According to the limited information available from user websites and clinical case reports, NBOMes have been sold as a ‘legal’ alternative to LSD (“legal LSD”) or as LSD due to the very potent psychedelic activity (Bersani et al., 2014; EMCDDA, 2014; World Health Organization, 2014a, b; UNODC, 2017). 25I-NBOMe was found in blotters seized in China sold as LSD (Zhang et al., 2018). A recent report from Columbia documents identification of 25I-NBOMe in 21 out of 70 blotters marked as LSD; the drug was combined in the same blotter with MDMA, 25I-NBOMe amine, and/or 25H-NBOMe (Mendoza-Valencia et al., 2019). NBOMes (25I-, 25C-, 25B-, and 25H-) were also found in tablets sold as Ecstasy (Chia et al., 2019). Thus, users may accidentally ingest NBOMe as counterfeited LSD or MDMA. According to information given on drug fora, users may find that LSD has a slight metallic taste or no taste at all, while 25I-NBOMe will have a bitter taste. The two substances can also be tested using a black light/UV source: LSD will glow whereas 25I-NBOMe will not (Zamnesia Blog, 2016).
Similar to other NPSs, users may combine NBOMes with various psychoactive substances: psychedelics (e.g., 2C compounds, mescaline, psilocybin and LSD), empathogens, psychostimulants, and/or depressants, including alcohol and marijuana, and medicines, both intentionally and unintentionally (Halberstadt, 2017; Madsen et al., 2017; Marchi et al., 2019). Importantly, the use of serotoninergic drugs, e.g., selective serotonin re-uptake inhibitors (SSRIs) or MAO-A inhibitors and/or substances known to increase extracellular serotonin levels may increase the risk of developing serotonergic toxicity, the symptoms of which include tachycardia, hypertension, hyperthermia, muscle rigidity, and convulsions (Volpi-Abadie et al., 2013).
Effects Related to Use of NBOMes
NBOMes are used for recreational purposes and psychedelic/hallucinogenic experiences. Subjective ‘positive’ effects reported by users resemble those of other psychedysleptics and include euphoria, mild stimulation, mood lift, feelings of love and empathy, change in perception, ego softening, insight, brightened and vibrant colors, enhanced appreciation of music, strong closed/open eye visuals, enhanced tactile sensation, mental/physical stimulation, increase in associative and creative thinking, erotic, sexual thoughts and sensations, and life-changing spiritual experiences (Zuba et al., 2013; EMCDDA, 2014; World Health Organization, 2014a, b; Erowid.org). “Wow! Visuals are crazy, and the music is intense–waves of 3D objects have taken over my living room and everything looks beautiful! […] Amazing party drug! I don’t feel very stimulated even though this is a psychedelic stimulant? But euphoria I feel quite allot, and this is a really social drug, although on high doses it’s a bit hard to have a real conversation.” “I literally FEEL the beauty of the universe in its infinite complexity. My perception of myself is erased. There is no longer a ‘me”’. “I am most certainly in a profound psychedelic headspace” (i.e., I intuitively understand the universe, society, etc. It’s much more of a pure psychedelic than its non-benzyl substituted cousin 2C-I while still retaining some of the entactogen qualities.” (Erowid.org).
NBOMes produce an array of adverse effects (Hill et al., 2013; Rose et al., 2013; Bersani et al., 2014; EMCDDA, 2014; Forrester, 2014; Grautoff and Kähler, 2014; Lawn et al., 2014; Stellpflug et al., 2014; Suzuki et al., 2014; Tang et al., 2014; World Health Organization, 2014a, b; Hieger et al., 2015; Nikolaou et al., 2015; Poklis et al., 2015b; Srisuma et al., 2015; Wood et al., 2015; Gee et al., 2016; Kristofic et al., 2016; Hermanns-Clausen et al., 2017; Humston et al., 2017; Madsen et al., 2017; Rajotte et al., 2017; Schetz et al., 2017; Wiergowski et al., 2017; Zygowiec et al., 2017; Marchi et al., 2019; Erowid.org); for comprehensive reviews see Suzuki et al., 2015; Halberstadt, 2017).
Psychoactive
Severe agitation, agitated delirium, intensive unpleasant hallucinations, aggression that sometimes progresses to violent and self-destructive behavior, paranoia, suicidal attempts, psychosis with delusions, dysphoria, irritability, fear, and panic attacks.
Neurological
Hyperthermia, convulsions, clonus, motor incoordination, mouth numbing and impaired speech, insomnia, blurred vision, and leucoencephalopathy.
Cognitive
Loss of location and time, confusion, short-term memory deficits, cognitive impairment, mental fatigue, altered mental state, loosening of association, and disorganized thoughts.
Cardiovascular
Tachycardia, hypertension, cardiac arrest, and vasoconstriction leading to ischemia.
Miscellaneous
Nausea, vomiting, sweating/chills, diaphoresis, tachypnea, respiratory and metabolic acidosis, leukocytosis, hyperglycemia, hyperkalemia, muscle rigidity, and compartment syndrome.
In severe cases, the use of NBOMes can led to comas, disseminated intravascular coagulation, liver failure, heart failure, pulmonary edema, cardiopulmonary arrest, rhabdomyolysis [a case of massive rhabdomyolysis with serum kinase creatinine concentration over 500,000 U/I was reported after ingestion of a 25I-NBOMe containing party pill named “Alice in Wonderland” (Schetz et al., 2017)], acute kidney failure, and multiorgan failure.
Srisuma et al. (2015) analyzed 148 cases of intoxication with NBOMe drugs and 193 with 2C compounds reported to the National Poison Data System in the United States from 1st September 2012 to 30th September 2014. They reported higher numbers of hallucinations/delusions, single-episode seizures, and benzodiazepine administration in NBOMe exposures (40.5, 8.8, and 50.0%, respectively) than those of 2C exposures (25.4, 3.1, and 32.6%, respectively).
In general, the features of NBOMe toxicity are also induced by other psychedelics. The main difference is an intensity and frequency of severe intoxication symptoms. The incidence of seizures is higher with NBOMes compared with other psychedysleptics, whereas muscle spasms, hyperreflexia, and tremors are rarely noted in cases of intoxication with NBOMes. The progression from rhabdomyolysis to metabolic acidosis, anuria, and acute renal failure is a common complication of severe NBOMe toxicity, but this is reported less frequently in cases of intoxication with other drugs.
By analogy to other NPSs, except for opioids and benzodiazepines, at present there are no specific antidotes for NBOMes, and all treatments used are symptomatic. Clinical management of acute toxicity resulting from the use of NBOMe compounds consists of monitoring, including fluids, electrolytes, acid-base balance, and supportive treatment: mechanical ventilation and intravenous administration of fluids; benzodiazepines (e.g., midazolam and lorazepam) given intravenously are used for sedation, to treat aggression, tremors, and convulsions; an infusion of catecholamines (noradrenaline, dopamine) to overcome sinus bradycardia; antiarrhythmic drugs (e.g., cardioselective β-blockers, amiodarone) to treat supraventricular tachyarrhythmia; and antipyretics/mechanical cooling in cases of hyperthermia. Gross hematuria and anuria require continuous venovenus hemodialysis (CVVHD), while oliguria demands CVVHD with citrate calcium. Patients with hematological disturbances require transfusion(s) of blood preparations (frozen plasma, frozen erythrocytes, or platelet concentrate). Severely aggressive patients may require antipsychotic drugs in addition to benzodiazepines (Hill et al., 2013; Rose et al., 2013; Forrester, 2014; Stellpflug et al., 2014; Hieger et al., 2015; Gee et al., 2016; Humston et al., 2017; Schetz et al., 2017; Wiergowski et al., 2017). Some emergency interventions are specifically intended to treat rhabdomyolysis, which may lead to severe complications, particularly acute kidney injury/failure and metabolic acidosis. They include discontinuation of further skeletal muscle damage by infusion of muscle relaxants (midazolam, rocuronium), early and aggressive fluid administration with a goal of maintaining an urinary flow of 200–300 mL/h, as well as urine alkalization to prevent myoglobin precipitation in a renal tract and management of hyperkalemia and hypocalcemia (Tang et al., 2014; Cervellin et al., 2017; Schetz et al., 2017)
Table 2 presents clinical fatality cases due to intoxication with NBOMes.
Table 2. Fatal cases related to use of NBOMe compounds.
Biotransformation
In recent years, biotransformation studies have been carried out for many NBOMe compounds. The metabolites have mainly been identified via in vitro study with microsomes and polled human hepatocytes or by the analysis of mouse or rat urine or authentic human samples of blood and urine collected from drug users. An accumulating body of data clearly indicates that NBOMes undergo extensive biotransformation that results in the production of numerous metabolites. For example, Caspar et al. (2015, 2017, 2018c, 2018d) list more than 60 metabolites for each of the analogs, 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe, as well as 36 phase I and 33 phase II metabolites for 4-EA-NBOMe, 17 phase I and 21 phase II metabolites for 3,4-DMA-NBOMe, and 19 phase I and 14 phase II metabolites for 4-MMA-NBOMe. The calculated intrinsic clearance values for 25I-NBOMe and 25I-NBOH were found to be 70.1 and 118.7 mL/min/kg, respectively (Nielsen et al., 2017).
The reported biotransformation steps include oxidative deamination, oxidative N-dealkylation also in combination with hydroxylation, oxidative O-demethylation possibly combined with hydroxylation, oxidation of secondary alcohols, mono- and dihydroxylation, oxidation of primary alcohols, and carboxylation of primary alcohols (Figure 2). In the case of 25N-NBOMe, reduction of the aromatic nitro group and N-acetylation of the primary aromatic amine have also been reported. The dominant phase I biotransformation was O-demethylation, followed by O-di-demethylation and hydroxylation; accordingly, the most abundant metabolites were the O-demethylated and hydroxylated forms. The major cytochrome P450 isoenzymes involved in the metabolism of NBOMes were identified as CYP1A2, CYP3A4, CYP2B6, CYP2C9, CYP2C19, and CYP2D6 (Caspar et al., 2015, 2018b,c,d; Nielsen et al., 2017; Richter et al., 2019). Phase I metabolites subsequently undergo glucuronidation and sulfation (Caspar et al., 2015; Leth-Petersen et al., 2016; Temporal et al., 2017; Wohlfarth et al., 2017; Richter et al., 2019; Seo H. et al., 2019).
Figure 2. Main phase I metabolic pathways of 25I-NBOMe.
Forensic casework samples have also identified demethyl metabolites of 25C-NBOMe (Soh and Elliott, 2014; Andreasen et al., 2015). Poklis et al. (2015a) analyzed urine samples from two patients intoxicated with 25I-NBOMe. One sample contained 25I-NBOMe together with 15 metabolites, while the other contained no parent 25I-NBOMe; it was found to contain three O-demethyl metabolites. Seven 25I-NBOMe metabolites were detected in the urine of a severely intoxicated man: two demethyl-25I-NBOMe, one demethyl-hydroxy-25I-NBOMe, one hydroxy-25I-NBOMe, one di-demethyl-25I-NBOMe, one demethyl-25I-NBOMe glucuronide, and one hydroxy-25I-NBOMe glucuronide (Richeval et al., 2017). The presence of 25H-NBOMe in biological samples of people who used both 25B-NBOMe and 25I-NBOMe (Soh and Elliott, 2014; Stellpflug et al., 2014) suggests an alternative route of NBOMes biotransformation, i.e., removal of the halogen atom. However, it is also possible that 25H-NBOMe is not formed during metabolic processes in the body but, more likely, is already present in the consumed product as a contaminant. Assuming that the halogenation step performed during synthesis in a clandestine laboratory was incomplete and the unreacted material was not adequately removed by purification, it appears likely that 25H-NBOMe could be present in the final drug product.
The fact that NBOMe compounds undergo extensive first-pass metabolism by the liver (Leth-Petersen et al., 2016; Halberstadt, 2017) fits well with data demonstrating very fast clearance of parent compounds from plasma. This makes the signals of the parent compounds approximately 100-fold lower than those of the most abundant metabolites (Stellpflug et al., 2014; Leth-Petersen et al., 2016). The significantly greater intensity of glucuronated metabolites when compared to the parent compounds in plasma make them prime candidates to be used as markers for NBOMe intoxication (Leth-Petersen et al., 2016).
An important issue worth pointing out is the fact that metabolites can also be responsible for the toxic effects of NBOMes (Leth-Petersen et al., 2016). Two other groups of active formed compounds, which are also sold on the drug market, include 2C phenethylamines or NBOH derivatives (Pasin et al., 2015; Nisbet et al., 2019). For all investigated NBOMes, the corresponding 2,5-dimethoxyphenethylamine (2C-X) metabolite formed during N-demethoxybenzylation was detected; however, they were mostly seen at low levels (Temporal et al., 2017; Grafinger et al., 2018).
Detection and Identification of NBOMes and Their Metabolites in Biological Materials
Due to the high receptor affinities of NBOMes and functional activities as full agonists, only very low doses, often in the range of 50–1000 μg, are needed to induce psychoactive effects, and, as a consequence, the resulting biological fluid concentrations tend to be very low, ranging from about 0.1 ng/mL to several ng/mL in blood and up to several dozen ng/mL in urine. Hence, only sensitive and specific analytical methods can be used for the detection, identification, and determination of NBOMes in biological materials (Kyriakou et al., 2015). Even in post-mortem cases, the reported blood concentrations of NBOMe compounds also tend to be low and are often below 0.5 ng/mL (Anilanmert et al., 2018). Although the compounds are generally present at higher concentrations in urine than in blood, detection methods should be targeted to the metabolites rather than the parent compounds.
The analysis of NBOMes can be a challenging task, even for laboratories equipped with sensitive modern methods, and popular immunochemical tests are not effective. Common analytical methods used in laboratories, such as gas chromatography coupled with mass spectrometry (GC-MS) or high-performance liquid chromatography with diode array detection (HPLC-DAD) without derivatization of the sample, are also inadequate for identifying NBOMe compounds due to insufficient sensitivity. Analytical methods must have low limits of detection (LOD); therefore, the most common techniques of detection of NBOMes in biological fluids are those implementing tandem mass spectrometry (MS-MS). Both high-performance liquid chromatography (HPLC or LC) and ultra-performance liquid chromatography (UPLC) coupled to either MS-MS or high resolution time-of-flight spectrometry (TOF-MS) are preferred. This latter technique allows for accurate determination of molecular and fragmentation ions, which in turn makes it possible to elucidate the chemical structure of compounds and consequently unambiguously identify not only the parent substance but also many metabolites. For the isolation of NBOMes from blood (as well as serum or plasma) and urine both liquid-liquid extraction (LLE) and solid phase extraction (SPE) can be used. Sometimes, a simple precipitation or just a dilution of a sample is sufficient.
Although many methods have been developed for the detection of NBOMe analogs in biological materials, both in metabolic studies and authentic forensic sample analyses, only a few screening methods covering more than one or two NBOMe compounds have been published. Caspar et al. (2018a) developed a method for the identification and determination of 21 low-dosed psychedelics and opioids, including 25B-NBOMe, 25C-NBOMe, 25E-NBOMe, 25I-NBOMe, and 25H-NBOMe, in blood plasma. A diethyl ether:ethyl acetate mixture was applied for a two-step extraction. Analyses were carried out using LC high resolution (HR) MS (orbitrap analyzer) with alternating HR full scan (HRFS) MS and “All-ions fragmentation” (AIF) MS. The approach allowed the detection of these analytes down to concentrations of 0.1 ng/mL.
Pasin et al. (2015) developed and validated an analytical method for the detection and quantification of 37 new designer drugs, including 25B-NBOMe, 25C-NBOMe, 25H-NBOMe, and 25I-NBOMe in the whole blood. Salting-out-assisted LLE with acetonitrile was performed to isolate compounds, followed by LC with an analysis combined with a quadrupole time-of-flight mass spectrometer (Q-TOF-MS). The method required only 100 μL of blood, but the limits of detection for NBOMe compounds was relatively high at 5 ng/mL. Temporal et al. (2017) describe the analysis of the same set of NBOMes with their major metabolites in blood and urine samples by UPLC-Q-TOF system; authentic samples underwent LLE before analysis using an n-butyl chloride:ethyl acetate mixture.
Poklis et al. (2014a) described the use of the LC-MS-MS method for the identification and quantification of nine NBOMe derivatives (25H-NBOMe, 2CC-NBOMe, 25I-NBF, 25D-NBOMe, 25B-NBOMe, 2CT-NBOMe, 25I-NBMD, 25G-NBOMe, and 25I-NBOMe) in human urine. The method used dilution of urine samples and extraction by Clean Screen FAStTM SPE columns to reduce the amount of matrix. A Q-Trap apparatus was used in multiple reaction monitoring (MRM) acquisition mode, which allowed the compounds to be detected at a level of 0.1 ng/mL. SPE was also used to identify and quantify five different 25-NBOMes (25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25H-NBOMe, and 25I-NBOMe) in blood and urine. The applied LC–MS-MS (Q-Trap) system allowed LOD to be obtained at a level of 0.05 ng/mL (Morini et al., 2017).
The UPLC-MS-MS (Q-Trap) system was used for the simultaneous quantification of six NBOMe analogs (25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25H-NBOMe, 25I-NBOMe, and 25T2-NBOMe) in the whole blood, plasma, and urine. The SPE was performed with the use of UCT Clean Screen DAU mixed mode columns. The method, characterized by LODs as low as 0.005–0.01 ng/mL, offered sufficient sensitivity to detect any of these compounds following use (Johnson et al., 2014).
Caspar et al. (2017) analyzed 25B-NBOMe and 25C-NBOMe along with their metabolites in human and rat urine. Depending on the experiment, urine was either incubated with a mixture of glucuronidase/arylsulfatase and then extracted with the use an HCX SPE columns or just precipitated with acetonitrile. The obtained samples were analyzed on the LC-HR-MS/MS system. In subsequent studies, nanoLC-HRMS/MS and UHPLC-HRMS/MS systems were applied for the detection and identification of metabolites of 3,4-DMA-NBOMe and 4-MMA-NBOMe (Caspar et al., 2018c). Urine samples were analyzed directly after dilution. Mass spectrometers were operated in positive ionization mode using full scan (FS) data and a subsequent data-dependent acquisition (DDA) mode. Both applied systems were comparable, but nanoLC allowed much lower eluent consumption: flow rate of 0.7 μL/min for nanoLC compared to 500–800 μL/min for UHPLC. Wohlfarth et al. (2017) also employed the simple dilution of urine to analyze samples with or without a prior hydrolysis step (with ß-glucuronidase/arylsulfatase mixture). 25C-NBOMe and 25I-NBOMe, and their metabolites, were detected and identified by LC-QTOF-MS in DDA mode (Wohlfarth et al., 2017).
Yu et al. (2019) proposed a new method of NBOMes identification. The fragmentation patterns of nine NBOMe derivatives (25H-NBOMe, 25B-NBOMe, 25E-NBOMe, 25N-NBOMe, 25C-NBOH, 25I-NBOH, 25B-NBF, 25C-NBF, and 25I-NBF) were analyzed using LC-QTOF-MS and an approach known as molecular networking, one that organizes MS-MS data by mining the MS-MS fragmentation similarity. The resulting MS-MS spectral data was used to establish a molecular networking map for different NBOMes, as these compounds generally showed similar product ion spectral patterns. The map was applied to spiked urine samples, confirming that it can be used for the rapid detection and identification of unknown NBOMes.
In addition to body fluids, other biological materials have also been analyzed for NBOMe compounds, including post-mortem tissues. Tissue homogenates were subjected to SPE using UCT mixed mode silica-based columns. LC–MS-MS analyses were performed on a Q-Trap apparatus (Kristofic et al., 2016). A validated method for the detection of 32 NPS, including 25C-NBOMe, 25B-NBOMe, and 25T4-NBOMe, in oral fluid has also been presented in which samples were prepared using a simple protein precipitation in acetonitrile and analyzed using the UHPLC-MS-MS system. All analytes were found to have a LOD at 1 ng/mL (Williams et al., 2017). Ameline et al. (2017) presented an analysis of hair samples (9.5 cm) collected in an acute poisoning case. The hairs were collected 6.5 months after a drug consumption and were analyzed by UPLC-MS-MS working in MRM mode. As a result of the analyses, the presence of 25I-NBOMe was demonstrated in two of five 2 cm hair segments at concentrations of 1.0 pg/mg and 4.9 pg/mg.
GC-MS is used less frequently but it can be a great tool in screening analyses when used in combination with a derivatization step. A validated GC-MS method for the quantification of 23 NPSs, including 25B-NBOME, 25C-NBOME, 25D-NBOMe, 25E-NBOME, 25H-NBOME, 25I-NBOME, Mescaline-NBOME, and 25P-NBOME in blood and urine samples have been presented. Sample preparation was carried out using SPE followed by derivatization with pentafluoropropionic anhydride (PFPA). The LODs for NBOMes were in the range of 0.2–0.3 ng/mL in urine and 0.3–0.4 ng/mL in blood. It should be emphasized that the proposed method can be used for detection of NBOMes in acute fatalities by laboratories that do not have access to an LC–MS-MS (Nisbet et al., 2019).
Concluding Remarks
In recent years, NBOMe derivatives, a specific set of psychedelic phenylalkylamines, have been encountered on the drugs of abuse market. These compounds are used in very low doses (in the range between 50 and 1000 μg) due to their high pharmacological activity. NBOMe drugs are highly toxic and their intake has been associated with severe adverse reactions including deaths. The analysis of NBOMes and their metabolites is a challenging task; only sensitive and specific analytical methods can be used for their detection, identification, and determination in biological materials.
Author Contributions
JZ: literature search, writing the sections “Abstract,Introduction, Methods, Pharmacology of NBOMes, Toxicity in vitro, Available forms of products, Pattern of use, Effects related to use of NBOMes, and Concluding remarks.” MK: preparation of tables and co-writing the section “Effects related to use of NBOMes.” PA: writing the sections “Detection and identification of NBOMes and their metabolites in biological materials, Biotransformation”; preparation of figures, and literature search.
Funding
This work was supported by the Medical University of Łódź (grant no. 503/3-011-01/503-31-001-19-00).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Abiero, A., Botanas, C. J., Sayson, L. V., Custodio, R. J., de la Peña, J. B., Kim, M., et al. (2019). 5-Methoxy-α-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex. Behav. Brain Res. 359, 828–835. doi: 10.1016/j.bbr.2018.07.020
Aghajanian, G. K., and Marek, G. J. (1999). Serotonin and hallucinogens. Neuropsychopharmacology 21(Suppl. 2), 16–23. doi: 10.1016/S0893-133X(98)00135-3
Al-Iman, A., and AbdulMajeed, B. A. (2017). NBOMe compounds: systematic review and data crunching of the surface web. Glob. J. Health Sci. 9, 126–139.
Ameline, A., Farrugia, A., Raul, J. S., and Kintz, P. (2017). Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis. Curr. Pharm. Biotechnol. 18, 786–790. doi: 10.2174/1389201019666171129175148
Andrabi, S., Greene, S., Moukaddam, N., and Li, B. (2015). New drugs of abuse and withdrawal syndromes. Emerg. Med. Clin. North Am. 33, 779–795. doi: 10.1016/j.emc.2015.07.006
Andreasen, M. F., Telving, R., Rosendal, I., Eg, M. B., Hasselstrøm, J. B., and Andersen, L. V. (2015). A fatal poisoning involving 25C-NBOMe. Forensic Sci. Int. 251, 1–8. doi: 10.1016/j.forsciint.2015.03.012
Anilanmert, B., Yonar, C. F., and Andaç, S. C. (2018). “NBOMe derivatives of phenylethylamines and their analysis,” in Chromatographic Techniques in the Forensic Analysis of Designer Drugs, eds T. Kowalska, M. Sajewicz, and J. Sherma, (Boca Raton, FL: CRC Press), 305–328. doi: 10.1201/9781315313177-16
Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., and Bolzan Mariotti et al. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res. Int. 2014:734749. doi: 10.1155/2014/734749
Bortolozzi, A., Díaz-Mataix, L., Scorza, M. C., Celada, P., and Artigas, F. (2005). The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95, 1597–1607. doi: 10.1111/j.1471-4159.2005.03485.x
Braden, M. R., Parrish, J. C., Naylor, J. C., and Nichols, D. E. (2006). Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol. 70, 1956–1964. doi: 10.1124/mol.106.028720
Caspar, A. T., Brandt, S. D., Stoever, A. E., Meyer, M. R., and Maurer, H. H. (2017). Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MSn, and LC–HR–MS/MS approaches. J. Pharm. Biomed. Anal. 134, 158–169. doi: 10.1016/j.jpba.2016.11.040
Caspar, A. T., Helfer, A. G., Michely, J. A., Auwärter, V., Brandt, S. D., Meyer, M. R., et al. (2015). Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS. Anal. Bioanal. Chem. 407, 6697–6719. doi: 10.1007/s00216-015-8828-6
Caspar, A. T., Kollas, A. B., Maurer, H. H., and Meyer, M. R. (2018a). Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry. Talanta 176, 635–645. doi: 10.1016/j.talanta.2017.08.063
Caspar, A. T., Meyer, M. R., and Maurer, H. H. (2018b). Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol. Lett. 285, 1–8. doi: 10.1016/j.toxlet.2017.12.017
Caspar, A. T., Meyer, M. R., Westphal, F., Weber, A. A., and Maurer, H. H. (2018c). Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine. Talanta 188, 111–123. doi: 10.1016/j.talanta.2018.05.064
Caspar, A. T., Westphal, F., Meyer, M. R., and Maurer, H. H. (2018d). LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl]propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Anal. Bioanal. Chem. 410, 897–912. doi: 10.1007/s00216-017-0526-0
Cervellin, G., Comelli, I., Benatti, M., Sanchis-Gomar, F., Bassi, A., and Lippi, G. (2017). Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management. Clin. Biochem. 50, 656–662. doi: 10.1016/j.clinbiochem.2017.02.016
Chan, S., Wu, J., and Lee, B. (2019). Fatalities related to new psychoactive substances in Singapore – A case series. Forensic Sci. Int. 304:109892. doi: 10.1016/j.forsciint.2019.109892
Chia, X. W. S., Ong, M. C., Yeo, Y. Y. C., Ho, Y. J., Binte Ahmad, Nasir, E. I., et al. (2019). Simultaneous analysis of 2Cs, 25-NBOHs, 25-NBOMes and LSD in seized exhibits using liquid chromatography-tandem mass spectrometry: a targeted approach. Forensic Sci. Int. 301, 394–401. doi: 10.1016/j.forsciint.2019.05.036
Custodio, R. J. P., Sayson, L. V., Botanas, C. J., Abiero, A., You, K. Y., and Kim, M. (2019). 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential. Addict. Biol. e12850. doi: 10.1111/adb.12850
Drug Enforcement Administration (2018). 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe (Street Names: N-bomb, Smiles, 25I, 25C, 25B). Available at: https://www.deadiversion.usdoj.gov/drug_chem_info/nbome.pdf (accessed December 1, 2019).
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., et al. (2018). Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142, 240–250. doi: 10.1016/j.neuropharm.2018.02.033
EMCDDA (2014). Report on the Risk Assessment of 2-(4-iodo-2,5-Dimethoxyphenyl)-N-(2-Methoxybenzyl)Ethanamine (25I-NBOMe) in the Framework of the Council Decision on New Psychoactive Substances. Available at: http://www.emcdda.europa.eu/system/files/publications/772/TDAK14001ENN_480887.pdf (accessed June 5, 2019).
EMCDDA (2019). European Drug Report 2019: Trends and Developments. Available at: http://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf (accessed July 5, 2019).
Erowid.org. Available at: https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_effects.shtml (accessed December 8, 2019).
Eshleman, A. J., Wolfrum, K. M., Reed, J. F., Kim, S. O., Johnson, R. A., and Janowsky, A. (2018). Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem. Pharmacol. 158, 27–34. doi: 10.1016/j.bcp.2018.09.024
Ettrup, A., da Cunha-Bang, S., McMahon, B., Lehel, S., Dyssegaard, A., Skibsted, A. W., et al. (2014). Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J. Cereb. Blood Flow Metab. 34, 1188–1196. doi: 10.1038/jcbfm.2014.68
Ettrup, A., Palner, M., Gillings, N., Santini, M. A., Hansen, M., Kornum, B. R., et al. (2010). Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J. Nucl. Med. 51, 1763–1770. doi: 10.2967/jnumed.109.074021
Forrester, M. B. (2014). NBOMe designer drug exposures reported to Texas poison centers. J. Addict. Dis. 33, 196–201. doi: 10.1080/10550887.2014.950027
Gatch, M. B., Dolan, S. B., and Forster, M. J. (2017). Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents. Behav. Pharmacol. 28, 375–385.
Gee, P., Schep, L. J., Jensen, B. P., Moore, G., and Barrington, S. (2016). Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases. Clin. Toxicol. (Phila) 54, 141–146. doi: 10.3109/15563650.2015.1115056
Glennon, R. A., Titeler, M., and McKenney, J. D. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2505–2511. doi: 10.1016/0024-3205(84)90436-3
Grafinger, K. E., Stahl, K., Wilke, A., König, S., and Weinmann, W. (2018). In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models. Drug Test. Anal. 10, 1607–1626. doi: 10.1002/dta.2446
Grautoff, S., and Kähler, J. (2014). Near fatal intoxication with the novel psychoactive substance 25C-NBOMe. Med. Klin. Intensivmed. Notfmed. 109, 271–275. doi: 10.1007/s00063-014-0360-5
Halberstadt, A. L. (2017). Pharmacology and toxicology of N-benzylphenethylamine (“NBOMe”) hallucinogens. Curr. Top. Behav. Neurosci. 32, 283–311. doi: 10.1007/7854_2016_64
Halberstadt, A. L., and Geyer, M. A. (2010). LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology (Berl) 208, 179–189. doi: 10.1007/s00213-009-1718-x
Halberstadt, A. L., and Geyer, M. A. (2014). Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77, 200–207. doi: 10.1016/j.neuropharm.2013.08.025
Halberstadt, A. L., and Geyer, M. A. (2018). Effect of hallucinogens on unconditioned behavior. Curr. Top. Behav. Neurosci. 36, 159–199. doi: 10.1007/7854_2016_466
Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., et al. (2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem. Neurosci. 5, 243–249. doi: 10.1021/cn400216u
Heim, R. (2003). Synthese und Pharmakologie Potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Ph.D. thesis, Free Universität Berlin, Berlin.
Herian, M., Wojtas, A., Kamińska, K., Swit, P., Wach, A., and Gołembiowska, K. (2019). Hallucinogen-like action of the novel designer drug 25I-NBOMe and its effect on cortical neurotransmitters in rats. Neurotox. Res. 36, 91–100. doi: 10.1007/s12640-019-00033-x
Hermanns-Clausen, M., Angerer, V., Kithinji, J., Grumann, C., and Auwärter, V. (2017). Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. Clin. Toxicol. (Phila) 55, 922–924. doi: 10.1080/15563650.2017.1319572
Hieger, M. A., Rose, S. R., Cumpston, K. L., Stromberg, P. E., Miller, S., and Wills, B. K. (2015). Severe poisoning after self-reported use of 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, a novel substituted amphetamine: a case series. Am. J. Emerg. Med. 33:1843.e1–3. doi: 10.1016/j.ajem.2015.04.065
Hill, S. L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M., et al. (2013). Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin. Toxicol. (Phila) 51, 487–492. doi: 10.3109/15563650.2013.802795
Humston, C., Miketic, R., Moon, K., Ma, P., and Tobias, J. (2017). Toxic leukoencephalopathy in a teenager caused by the recreational ingestion of 25I-NBOMe: a case report and review of literature. J. Med. Cases 8, 174–179. doi: 10.14740/jmc2811w
Ísberg, V., Balle, T., Sander, T., Jørgensen, F. S., and Gloriam, D. E. (2011). G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations. J. Chem. Inf. Model. 51, 315–325. doi: 10.1021/ci100402f
Jeon, S. Y., Kim, Y. H., Kim, S. J., Suh, S. K., and Cha, H. J. (2019). Abuse potential of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe); in vivo and ex vivo approaches. Neurochem. Int. 125, 74–81. doi: 10.1016/j.neuint.2019.02.007
Johnson, R. D., Botch-Jones, S. R., Flowers, T., and Lewis, C. A. (2014). An evaluation of 25B-, 25C-, 25D-, 25H-, 25I- and 25T2-NBOMe via LC-MS-MS: method validation and analyte stability. J. Anal. Toxicol. 38, 479–484. doi: 10.1093/jat/bku085
Juncosa, J. I. Jr., Hansen, M., Bonner, L. A., Cueva, J. P., Maglathlin, R., McCorvy, J. D., et al. (2013). Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. ACS Chem. Neurosci. 14, 96–109. doi: 10.1021/cn3000668
Kristofic, J. J., Chmiel, J. D., Jackson, G. F., Vorce, S. P., Holler, J. M., Robinson, S. L., et al. (2016). Detection of 25C-NBOMe in three related cases. J. Anal. Toxicol. 40, 466–472. doi: 10.1093/jat/bkw035
Kueppers, V. B., and Cooke, C. T. (2015). 25I-NBOMe related death in Australia: a case report. Forensic Sci. Int. 249, e15–18. doi: 10.1016/j.forsciint.2015.02.010
Kyriakou, C., Marinelli, E., Frati, P., Santurro, A., Afxentiou, M., Zaami, S., et al. (2015). NBOMe: new potent hallucinogens–pharmacology, analytical methods, toxicities, fatalities: a review. Eur. Rev. Med. Pharmacol. Sci. 19, 3270–3281.
Lawn, W., Barratt, M., Williams, M., Horne, A., and Winstock, A. (2014). The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J. Psychopharmacol. 28, 780–788. doi: 10.1177/0269881114523866
Leth-Petersen, S., Gabel-Jensen, C., Gillings, N., Lehel, S., Hansen, H. D., Knudsen, G. M., et al. (2016). Metabolic fate of hallucinogenic NBOMes. Chem. Res. Toxicol. 29, 96–100. doi: 10.1021/acs.chemrestox.5b00450
Lowe, L. M., Peterson, B. L., and Couper, F. J. (2015). A case review of the first analytically confirmed 25I-NBOMe-related death in Washington state. J. Anal. Toxicol. 39, 668–671. doi: 10.1093/jat/bkv092
Madsen, G. R., Petersen, T. S., and Dalhoff, K. P. (2017). NBOMe hallucinogenic drug exposures reported to the Danish Poison Information Centre. Dan. Med. J. 64:A5386.
Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., et al. (2019). Clinical and toxicological profile of NBOMes: a systematic review. Psychosomatics 60, 129–138. doi: 10.1016/j.psym.2018.11.002
Marti, M., Neru, M., Bilel, S., Di Paolo, M., La Russa, R., Ossato, A., et al. (2019). MDMA alone affects sensorimotor and prepulse inhibition responses in mice and rats: tips in the debate on potential MDMA unsafety in human activity. Forensic Toxicol. 37, 132–144. doi: 10.1007/s11419-018-0444-7
Mendoza-Valencia, C. Y., Mariño Gaviria, D. J., Patiño-Reyes, N., Lopez-Vallejo, F., Sarmiento Gutiérrez, ÁE., and Rodríguez, D. T. (2019). Mix of new substances psychoactive, NPS, found in blotters sold in two Colombian cities. Forensic Sci. Int. 304:109969. doi: 10.1016/j.forsciint.2019.109969
Miliano, C., Marti, M., Pintori, N., Castelli, M. P., Tirri, M., and Arfé, R. (2019). Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOMe. Front. Pharmacol. 10:1406. doi: 10.3389/fpharm.2019.01406
Morini, L., Bernini, M., Vezzoli, S., Restori, M., Moretti, M., Crenna, S., et al. (2017). Death after 25C-NBOMe and 25H-NBOMe consumption. Forensic Sci. Int. 279, e1–e6. doi: 10.1016/j.forsciint.2017.08.028
Muschamp, J. W., Regina, M. J., Hull, E. M., Winter, J. C., and Rabin, R. A. (2004). Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res. 1023, 134–140. doi: 10.1016/j.brainres.2004.07.044
Nichols, D. E., Sassano, M. F., Halberstadt, A. L., Klein, L. M., Brandt, S. D., Elliott, S. P., et al. (2015). N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues. ACS Chem. Neurosci. 6, 1165–1175. doi: 10.1021/cn500292d
Nielsen, L. M., Holm, N. B., Leth-Petersen, S., Kristensen, J. L., Olsen, L., and Linnet, K. (2017). Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. Drug Test. Anal. 9, 671–679. doi: 10.1002/dta.2031
Nikolaou, P., Papoutsis, I., Stefanidou, M., Spiliopoulou, C., and Athanaselis, S. (2015). 2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and legislative aspects. Drug Chem. Toxicol. 38, 113–119. doi: 10.3109/01480545.2014.911882
Nisbet, L. A., Wylie, F. M., Logan, B. K., and Scott, K. S. (2019). Gas chromatography-mass spectrometry method for the quantitative identification of 23 new psychoactive substances in blood and urine. J. Anal. Toxicol. 43, 346–352. doi: 10.1093/jat/bky109
Noworyta-Sokołowska, K., Kamińska, K., Kreiner, G., Rogóż, Z., and Gołembiowska, K. (2016). Neurotoxic effects of 5-MeO-DIPT: a psychoactive tryptamine derivative in rats. Neurotox. Res. 30, 606–619. doi: 10.1007/s12640-016-9654-0
Noworyta-Sokołowska, K., Kamińska, K., Rzemieniec, J., Wnuk, A., Wojcieszak, J., Górska, A. M., et al. (2019). Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats. Forensic Toxicol. 37, 45–58. doi: 10.1007/s11419-018-0433-x
Palamar, J. J., and Le, A. (2019). Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005–2017. Hum. Psychopharmacol. 34:e2690. doi: 10.1002/hup.2690
Pasin, D., Bidny, S., and Fu, S. (2015). Analysis of new designer drugs in post-mortem blood using high-resolution mass spectrometry. J. Anal. Toxicol. 39, 163–171. doi: 10.1093/jat/bku144
Pehek, E. A., Nocjar, C., Roth, B. L., Byrd, T. A., and Mabrouk, O. S. (2006). Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31, 265–277. doi: 10.1038/sj.npp.1300819
Poklis, J. L., Clay, D. J., and Poklis, A. (2014a). High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. J. Anal. Toxicol. 38, 113–121. doi: 10.1093/jat/bku005
Poklis, J. L., Dempsey, S. K., Liu, K., Ritter, J. K., Wolf, C., Zhang, S., et al. (2015a). Identification of metabolite biomarkers of the designer hallucinogen 25I-NBOMe in mouse hepatic microsomal preparations and human urine samples associated with clinical intoxication. J. Anal. Toxicol. 39, 607–616. doi: 10.1093/jat/bkv079
Poklis, J. L., Devers, K. G., Arbefeville, E. F., Pearson, J. M., Houston, E., and Poklis, A. (2014b). Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci. Int. 234, e14–e20. doi: 10.1016/j.forsciint.2013.10.015
Poklis, J. L., Raso, S. A., Alford, K. N., Poklis, A., and Peace, M. R. (2015b). Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine derivatives on blotter paper. J. Anal. Toxicol. 39, 617–623. doi: 10.1093/jat/bkv073
Poulie, C. B. M., Jensen, A. A., Halberstadt, A., and Kristensen, J. L. (2019). Dark classics in chemical neuroscience: NBOMes. ACS Chem. Neurosci. doi: 10.1021/acschemneuro.9b00528
Rajotte, J. W., Palmentier, J. F. P., and Wallage, H. R. (2017). Drug recognition evaluation and chemical confirmation of a 25C-NBOMe-impaired driver. J. Forensic Sci. 62, 1410–1413. doi: 10.1111/1556-4029.13433
Richeval, C., Boucher, A., Humbert, L., Phanithavong, M., Wiart, J. F., Moulsma, M., et al. (2017). Retrospective identification of 25I-NBOMe metabolites in an intoxication case. Toxicol. Anal. Clin. 29, 71–81. doi: 10.1016/j.toxac.2017.01.001
Richter, L. H. J., Menges, J., Brandt, S. D., Stratford, A., Westphal, F., Flockerzi, V., et al. (2019). In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry. Forensic Toxicol. 38, 141–159. doi: 10.1007/s11419-019-00498-7
Rickli, A., Luethi, D., Reinisch, J., Buchy, D., Hoener, M. C., and Liechti, M. E. (2015). Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99, 546–553. doi: 10.1016/j.neuropharm.2015.08.034
Rickli, A., Moning, O. D., Hoener, M. C., and Liechti, M. E. (2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol. 26, 1327–1337. doi: 10.1016/j.euroneuro.2016.05.001
Rose, S. R., Poklis, J. L., and Poklis, A. (2013). A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin. Toxicol. (Phila) 51, 174–177. doi: 10.3109/15563650.2013.772191
Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., and Jan, C. R. (1989). Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology (Berl) 98, 495–499. doi: 10.1007/bf00441948
Schechter, M. D. (1988). Serotonergic–dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacol. Biochem. Behav. 31, 817–824. doi: 10.1016/0091-3057(88)90390-5
Schetz, S., Waldman, W., Kocic, I., and Anand, J. S. (2017). A case of laboratory confirmed 25I-Nbome intoxication associated with massive rhabdomyolysis and multi-organ failure. Adv. J. Toxicol. Curr. Res. 1, 043–048.
Scruggs, J. L., Schmidt, D., and Deutch, A. Y. (2003). The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci. Lett. 346, 137–140. doi: 10.1016/s0304-3940(03)00547-0
Seo, H., Kim, I. S., Kim, Y. H., Yoo, H. H., and Hong, J. (2019). Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry. Int. J. Legal Med. 133, 833–841. doi: 10.1007/s00414-018-1904-7
Seo, J. Y., Hur, K. H., Ko, Y. H., Kim, K., Lee, B. R., Kim, Y. J., et al. (2019). A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res. Bull. 152, 19–26. doi: 10.1016/j.brainresbull.2019.07.002
Shanks, K. G., Sozio, T., and Behonick, G. S. (2015). Fatal intoxications with 25B-NBOMe and 25I-NBOMe in Indiana during 2014. J Anal. Toxicol. 39, 602–606. doi: 10.1093/jat/bkv058
Shintani-Ishida, K., Saka, K., Nakamura, M., Yoshida, K. I., and Ikegaya, H. (2018). Experimental study on the postmortem redistribution of the substituted phenethylamine, 25B-NBOMe. J. Forensic Sci. 63, 588–591. doi: 10.1111/1556-4029.13583
Shulgin, A., and Shulgin, A. (eds). (1991). Phenethylamines I Have Known and Loved (PiHKAL). Berkeley, CA: Transform Press.
Silva, M. E., Heim, R., Strasser, A., Elz, S., and Dove, S. (2011). Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J. Comput. Aided Mol. Des. 25, 51–66. doi: 10.1007/s10822-010-9400-2
Soh, Y. N., and Elliott, S. (2014). An investigation of the stability of emerging new psychoactive substances. Drug Test. Anal. 6, 696–704. doi: 10.1002/dta.1576
Srisuma, S., Bronstein, A. C., and Hoyte, C. O. (2015). NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin. Toxicol. (Phila) 53, 624–628. doi: 10.3109/15563650.2015.1054502
Stellpflug, S. J., Kealey, S. E., Hegarty, C. B., and Janis, G. C. (2014). 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J. Med. Toxicol. 10, 45–50. doi: 10.1007/s13181-013-0314-y
Suzuki, J., Dekker, M. A., Valenti, E. S., Arbelo Cruz, F. A., Correa, A. M., Poklis, J. L., et al. (2015). Toxicities associated with NBOMe ingestion–a novel class of potent hallucinogens: A review of the literature. Psychosomatics 56, 129–139. doi: 10.1016/j.psym.2014.11.002
Suzuki, J., Poklis, J. L., and Poklis, A. (2014). “My friend said it was good LSD”: a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J. Psychoactive Drugs 46, 379–382. doi: 10.1080/02791072.2014.960111
Tang, M. H., Ching, C. K., Tsui, M. S., Chu, F. K., and Mak, T. W. (2014). Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin. Toxicol. (Phila) 52, 561–565. doi: 10.3109/15563650.2014.909932
Temporal, K. H., Scott, K. S., Mohr, A. L. A., and Logan, B. K. (2017). Metabolic profile determination of NBOMe compounds using human liver microsomes and comparison with findings in authentic human blood and urine. J. Anal. Toxicol. 41, 646–657. doi: 10.1093/jat/bkx029p
Titeler, M., Lyon, R. A., and Glennon, R. A. (1988). Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94, 213–216. doi: 10.1007/bf00176847
TripSit a. Available at: http://drugs.tripsit.me//25b-nbome (accessed August 19, 2019).
TripSit b. Available at: http://drugs.tripsit.me//25c-nbome (accessed August 19, 2019).
TripSit c. Available at: http://drugs.tripsit.me//25e-nbome (accessed August 19, 2019).
TripSit d. Available at: http://drugs.tripsit.me//25i-nbome (accessed August 19, 2019).
TripSit e. Available at: http://drugs.tripsit.me/25n-nbome (accessed August 19, 2019).
Umemura, Y., Andrew, T., Jacobs, V., Giustini, A., Lewis, L., Hanowell, J., et al. (2014). Fatal outcome of status epilepticus, hyperthermia, rhabdomyolysis, multi-organ failure, and cerebral edema after 25I-NBOMe ingestion. Neurology, 82(Suppl. 10), 1.342.
United Nations Office on Drugs and Crime [UNODC] (2019). Current NPS Threats (2019) 1. Available from: https://www.unodc.org/pdf/opioids-crisis/Current_NPS_Threats_-_Volume_I.pdf (accessed December 5, 2019).
United Nations (2019). United Nations Office on Drugs and Crime. World Drug Report 2019. Booklet 5. Cannabis and Hallucinogens. Available at: https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_5_CANNABIS_HALLUCINOGENS.pdf (accessed December 5, 2019).
UNODC (2017). World Drug Report 2017. Booklet 4. Market Analysis of Synthetic Drugs. Amphetamine-Type Stimulants, New Psychoactive Substances. Available at: https://www.unodc.org/wdr2017/field/Booklet_4_ATSNPS.pdf (accessed December 5, 2019).
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Bäbler, A., Vogel, H., and Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897–3902. doi: 10.1097/00001756-199812010-00024
Walterscheid, J. P., Phillips, G. T., Lopez, A. E., Gonsoulin, M. L., Chen, H. H., and Sanchez, L. A. (2014). Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am. J. Forensic Med. Pathol. 35, 20–25. doi: 10.1097/PAF.0000000000000082
Wiergowski, M., Aszyk, J., Kaliszan, M., Wilczewska, K., Anand, J. S., Kot-Wasik, A., et al. (2017). Identification of novel psychoactive substances 25B-NBOMe and 4-CMC in biological material using HPLC-Q-TOF-MS and their quantification in blood using UPLC-MS/MS in case of severe intoxications. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 104, 1–10. doi: 10.1016/j.jchromb.2016.12.018
Williams, M., Martin, J., and Galettis, P. (2017). A validated method for the detection of 32 Bath Salts in oral fluid. J. Anal. Toxicol. 41, 659–669. doi: 10.1093/jat/bkx055
Willins, D. L., and Meltzer, H. Y. (1997). Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282, 699–706.
Wohlfarth, A., Roman, M., Andersson, M., Kugelberg, F. C., Diao, X., Carlier, J., et al. (2017). 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. Drug Test. Anal. 9, 680–698. doi: 10.1002/dta.2044
Wood, D. M., Sedefov, R., Cunningham, A., and Dargan, P. I. (2015). Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin. Toxicol. (Phila) 53, 85–92. doi: 10.3109/15563650.2015.1004179
World Health Organization (2014a). “25B−NBOMe critical review report agenda item 4.17,” in Proceedings of the Expert Committee on Drug Dependence Thirty-sixth Meeting 16−20 June 2014, Geneva.
World Health Organization (2014b) “25I−NBOMe Critical Review Report Agenda item 4.19,” in Proceedings of the Expert Committee on Drug Dependence Thirty-sixth Meeting 16−20 June 2014, Geneva.
Xu, P., Qiu, Q., Li, H., Yan, S., Yang, M., Naman, C. B., et al. (2019). 25C-NBOMe, a novel designer psychedelic, induces neurotoxicity 50 times more potent than methamphetamine in vitro. Neurotox. Res. 35, 993–998. doi: 10.1007/s12640-019-0012-x
Yoon, K. S., Yun, J., Kim, Y. H., Shin, J., Kim, S. J., Seo, J. W., et al. (2019). 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo. Toxicol. Lett. 304, 50–57. doi: 10.1016/j.toxlet.2019.01.004
Yu, J. S., Seo, H., Kim, G. B., Hong, J., and Yoo, H. H. (2019). MS-based molecular networking of designer drugs as an approach for the detection of unknown derivatives for forensic and doping applications: A case of NBOMe derivatives. Anal. Chem. 91, 5483–5488. doi: 10.1021/acs.analchem.9b00294
Zamnesia Blog (2016). Available at: https://www.zamnesia.com/blog-lsd-or-25i-nbome-how-to-tell-the-difference-n1096 (accessed August 10, 2019).
Zhang, X., Yanbiao, Z., Hongxian, Y., Lisheng, G., and Hui, Z. (2018). Seized blotters containing one regioisomer of 25I-NBOMe. J. Forensic Biomed 9:138. doi: 10.4172/2090-2697.1000138
Zuba, D., Sekuła, K., and Buczek, A. (2013). 25C-NBOMe – new potent hallucinogenic substance identified on the drug market. Forensic Sci. Int. 227, 7–14. doi: 10.1016/j.forsciint.2012.08.027
Zwartsen, A., Hondebrink, L., and Westerink, R. H. (2018). Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA). Neurotoxicology 66, 87–97. doi: 10.1016/j.neuro.2018.03.00
Zwartsen, A., Hondebrink, L., and Westerink, R. H. (2019). Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios. Neurotoxicology 74, 28–39. doi: 10.1016/j.neuro.2019.05.004
Keywords: new psychoactive substances, NBOMe, phenethylamines, psychedelics, toxicity, metabolism, analytical methods
Citation: Zawilska JB, Kacela M and Adamowicz P (2020) NBOMes–Highly Potent and Toxic Alternatives of LSD. Front. Neurosci. 14:78. doi: 10.3389/fnins.2020.00078
Received: 26 September 2019; Accepted: 20 January 2020;
Published: 26 February 2020.
Edited by:
Liana Fattore, Italian National Research Council, ItalyReviewed by:
Adam Halberstadt, University of California, San Diego, United StatesKenichi Tamama, University of Pittsburgh, United States
Copyright © 2020 Zawilska, Kacela and Adamowicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jolanta B. Zawilska, am9sYW50YS56YXdpbHNrYUB1bWVkLmxvZHoucGw=